PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH INTRAVITREAL RANIBIZUMAB AND LASER PHOTOCOAGULATION TARGETED TO ISCHEMIC RETINA
To compare panretinal photocoagulation (PRP) as described in the Early Treatment Diabetic Retinopathy Study (ETDRS) combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) and retinal photocoagulation targeted to ischemic retina combined with IVR (ISQ-RP) in patients with proliferative diabetic retinopathy (PDR)
Patients with PDR and no prior laser treatment were randomly assigned to receive either PRP plus IVR (“ETDRS-PRP” group) or retinal photocoagulation targeted to ischemic areas plus IVR (“ISQ-RP” group). PRP was administered in two sessions (at weeks 0 and 2) and IVR was administered at the end of the first laser session. Ophthalmic evaluation including ETDRS best-corrected visual acuity (BCVA), central subfield thickness (CSFT) measured by SD-OCT were performed at baseline and every 4 weeks through week 48. Area of fluorescein leakage from active new vessels (FLA) was measured by fluorescein angiography every 12 weeks until final visit. Additionally, full-field ERG was recorded at baseline and after 3 months follow-up
A total of 30 eyes from 22 patients were enrolled, but 22 completed the 48-week study period (12 eyes in the ETDRS-PRP group and 10 eyes in the ISQ-RP group). There was no significant difference between groups BCVA, CSFT or FLA at baseline (P > 0.05). Mean ± SE BCVA (logMAR) was 0.44 ± 0.07 and 0.37 ± 0.08; CSFT (µm) was 324.00 ± 20.44 and 330.07 ± 22.08 and FLA (mm2) was 16.1 ± 4.42 and 9.97 ± 1.83 for ETDRS-PRP and ISQ-RP groups, respectively. There was no relevant change on BCVA or CSFT during follow-up. A significant FLA reduction was observed at all follow-up visits compared to baseline for both groups, but there were no differences between groups. The mean number of IVR injections was 8 and 6.25 for the ETDRS-PRP and ISQ-RP groups, respectively
Retinal photocoagulation targeted to ischemic retinal areas proved as effective as EDTRS-PRP, both associated with IVR injections, in reducing FLA up to one year of follow-up
diabetic retinopathy. ranibizumab, panretinal photocoagulation
CLINICAL RETINA
Department of Ophthalmology, Otolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, Ribeirao Preto, SP, Brazil - São Paulo - Brasil
Rodrigo Jorge, Luiza Toscano, Katharina Messias, Jefferson Ribeiro, André Messias